Third Rock Ventures
Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace.Founded in 2007
Homepage: http://www.thirdrockventures.com/
HQ
02116 29 Newbury Street; 3rd FloorBoston
USA MA
Phone: (617) 585-2000
Third Rock Ventures at CrunchBase
Mark Levin CEO
Steven Paul Venture Partner
Keith Dionne Entrepreneur-in-residence
Ben Askew Entrepreneur-In-Residence
Past
Kevin Starr COO
April, 2013
Third Rock Ventures invested $12.5M in TARIS Biomedical as private_equity round
March, 2013
Third Rock Ventures invested $9M in DC Devices as a Series A round
February, 2013
Third Rock Ventures invested $11.5M in Kala Pharmaceuticals as a Series A round
Third Rock Ventures invested $47M in Jounce Therapeutics as a Series A round
December, 2012
Third Rock Ventures invested $21M in Zafgen as a Series D round
November, 2012
Third Rock Ventures invested $8M in Rhythm Pharmaceuticals as a Series B round
October, 2012
Third Rock Ventures invested $10M in Cibiem as a Series A round
September, 2012
Third Rock Ventures invested $42.5M in Foundation Medicine as a Series B round
Third Rock Ventures invested $38M in MyoKardia as a Series A round
July, 2012
Third Rock Ventures invested $60M in bluebird bio as a Series D round
June, 2012
Third Rock Ventures invested $40.7M in Global Blood Therapeutics as a Series A round
Third Rock Ventures invested $25M in Rhythm Pharmaceuticals as a Series B round
Third Rock Ventures invested $33M in Igenica as a Series C round
May, 2012
Third Rock Ventures invested $20M in Eleven Biotherapeutics as a Series A round
April, 2012
Third Rock Ventures invested $10M in Alcresta as a Series A round
March, 2012
Third Rock Ventures invested $6.2M in Kala Pharmaceuticals as unattributed round
January, 2012
Third Rock Ventures invested $125M in Warp Drive Bio as unattributed round
December, 2011
Third Rock Ventures invested $34M in Ember Therapeutics as a Series A round
November, 2011
Third Rock Ventures invested $78M in Agios Pharmaceuticals as a Series C round
Third Rock Ventures invested $15M in Allena Pharmaceuticals as a Series A round
October, 2011
Third Rock Ventures invested $33.5M in Foundation Medicine as a Series A round
Third Rock Ventures invested $35M in SAGE Therapeutics as a Series A round
Third Rock Ventures invested $27M in Topica Pharmaceuticals as a Series B round
July, 2011
Third Rock Ventures invested $33M in Zafgen as a Series C round
June, 2011
Third Rock Ventures invested $26M in Lotus Tissue Repair as a Series A round
Third Rock Ventures invested $15M in Constellation Pharmaceuticals as a Series B round
May, 2011
Third Rock Ventures invested $4.5M in Seventh Sense Biosystems as a Series A round
April, 2011
Third Rock Ventures invested $30M in bluebird bio as unattributed round
Third Rock Ventures invested $18.3M in TARIS Biomedical as a Series B round
Third Rock Ventures invested $40M in Blueprint Medicines as a Series A round
January, 2011
Third Rock Ventures invested $30M in PanOptica as a Series A round
November, 2010
Robert Kamen, a former executive-in-residence at Oxford BioScience Partners, has joined life sciences-focused venture capital firm Third Rock Ventures LLC in the same role
October, 2010
Third Rock Ventures invested $33M in NinePoint Medical as a Series A round
September, 2010
Third Rock Ventures invested $30M in CytomX Therapeutics as a Series B round
Third Rock Ventures announced today that it has closed on its oversubscribed Fund II, raising $426 million.
June, 2010
Third Rock Ventures invested $4.8M in Constellation Pharmaceuticals as a Series B round
Third Rock Ventures invested $12M in Ablexis as a Series A round
March, 2010
Third Rock Ventures invested $28M in Zafgen as a Series B round
Third Rock Ventures invested $35M in bluebird bio as a Series B round
Third Rock Ventures invested $35M in Eleven Biotherapeutics as a Series A round
December, 2009
Third Rock Ventures invested $23M in Afferent Pharmaceuticals as a Series A round
August, 2009
Third Rock Ventures invested $17.2M in Constellation Pharmaceuticals as a Series B round
October, 2008
Third Rock Ventures invested $20M in Alnara Pharmaceuticals as a Series A round
2007
Third Rock Ventures was founded in 2007